Cipla

The Indian equity indices on Friday traded lower led by selling pressure in information technology and pharma stocks during opening deals.

Drug major Cipla on Wednesday said that Naina Lal Kidwai has resigned as independent director on its board, with effect from March 31, 2022

Cipla on Tuesday reported a 2.6 per cent decline in its consolidated profit after tax to Rs 729 crore for the third quarter ended on December 31, 2021

Pharma Stocks Today: Pharmaceutical shares such as Cipla, Dr Reddy's Laboratories, Torrent Pharma, Sun Pharma Industries gained around two per cent each on Wednesday

The Indian equity benchmarks turned positive in a highly volatile trade on Monday led by gains in IT and pharma stocks.

The domestic stock markets are expected to trade cautiously on Wednesday, taking cues from the global markets.

The company's EBITDA or earnings before interest, tax, depreciation and amortisation also went up by 4.2 per cent to Rs 1,226.2 crore

Foreign institutional investors sold shares worth Rs 2,459 crore on Monday while domestic institutional investors bought shares worth Rs 2,390 crore.

Foreign institutional investors bought shares worth Rs 131 crore while domestic institutional investors sold shares worth Rs 613 crore on Friday.

Cipla shares have so far this year surged 22 per cent compared with 10 per cent gain in the Sensex.

Reliance Industries has signed a pact with Abu Dhabi National Oil Company to jointly build a petrochemicals facility in Ruwais, Abu Dhabi

Fivegeneric drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in the country.

The government on Tuesday cleared the fourth vaccine for emergency use in the country, the US-made Moderna.

The Monoclonal Antibody Cocktail used to treat mild to moderate "high risk" Covid patients is now available at Delhi's Lok Nayak Jai Prakash Narayan Hospital (LNJP) for free.

Seeking fast-track approvals to bring Moderna's single-dose COVID-19 booster vaccine in India expeditiously, Cipla has requested the government for indemnification and exemptions from price capping, bridging trials and basic customs duty.

The Indian equity indices on Friday traded lower led by selling pressure in information technology and pharma stocks during opening deals.

Drug major Cipla on Wednesday said that Naina Lal Kidwai has resigned as independent director on its board, with effect from March 31, 2022

Cipla on Tuesday reported a 2.6 per cent decline in its consolidated profit after tax to Rs 729 crore for the third quarter ended on December 31, 2021

Pharma Stocks Today: Pharmaceutical shares such as Cipla, Dr Reddy's Laboratories, Torrent Pharma, Sun Pharma Industries gained around two per cent each on Wednesday

The Indian equity benchmarks turned positive in a highly volatile trade on Monday led by gains in IT and pharma stocks.

The domestic stock markets are expected to trade cautiously on Wednesday, taking cues from the global markets.

The company's EBITDA or earnings before interest, tax, depreciation and amortisation also went up by 4.2 per cent to Rs 1,226.2 crore

Foreign institutional investors sold shares worth Rs 2,459 crore on Monday while domestic institutional investors bought shares worth Rs 2,390 crore.

Foreign institutional investors bought shares worth Rs 131 crore while domestic institutional investors sold shares worth Rs 613 crore on Friday.

Cipla shares have so far this year surged 22 per cent compared with 10 per cent gain in the Sensex.

Reliance Industries has signed a pact with Abu Dhabi National Oil Company to jointly build a petrochemicals facility in Ruwais, Abu Dhabi

Fivegeneric drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in the country.

The government on Tuesday cleared the fourth vaccine for emergency use in the country, the US-made Moderna.

The Monoclonal Antibody Cocktail used to treat mild to moderate "high risk" Covid patients is now available at Delhi's Lok Nayak Jai Prakash Narayan Hospital (LNJP) for free.

Seeking fast-track approvals to bring Moderna's single-dose COVID-19 booster vaccine in India expeditiously, Cipla has requested the government for indemnification and exemptions from price capping, bridging trials and basic customs duty.